Skip to content

Effect of Sublingual Supplementation with Resveratrol in patients with Renal Disease

Effect of Supplementation of Resveratrol Sublingual on Oxidative And Inflammatory Stress Markers in Hemodialysis Patients with Chronic Kidney Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-43mg87
Enrollment
Unknown
Registered
2017-10-17
Start date
2017-10-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Interventions

The patients will be divided into two groups (Control Group with 21 participants and Intervention Group with 21 participants), through a simple randomization list generated by the Research Randomizer
Dietary supplement
SP6.051.227

Sponsors

Universidade do Sul de Santa Catarina
Lead Sponsor
Universidade do Sul de Santa Catarina
Collaborator

Eligibility

Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients of both sexes; over the age of 19; diagnosis of chronic kidney disease and who have been on a regular hemodialysis program for at least 3 months, since this is the time used to confirm the chronicity of renal disease

Exclusion criteria

Exclusion criteria: Patients with a history of hypersensitivity to resveratrol will be excluded from the study; patients with food allergy containing resveratrol;cancer patients; with acute renal failure; in use of anti-inflammatory drugs; use of omega 3 supplementation; bedridden patients

Design outcomes

Primary

MeasureTime frame
Expected outcome 1: Reduction of serological inflammatory markers, verified by turbidimetry methods and enzyme-linked immunosorbent assay (ELISA), of at least 10%. Data collected before the intervention and 30 days after the intervention. ;Expected outcome 2: Reduction of serological oxidative stress markers, measured by spectrophotometry, of at least 10%. Data collected before the intervention and 30 days after the intervention.

Secondary

MeasureTime frame
Expected outcome 1: Improvement of the quality of life, evaluated by the questionnaire "quality of life for chronic kidney disease", of at least 20%. Data collected before the intervention and 30 days after the intervention.

Countries

Brazil

Contacts

Public ContactMaicon Kviecinski

Universidade do Sul de Santa Catarina

maicon.kviecinski@gmail.com+55 (48) 3279 1167

Outcome results

None listed

Source: REBEC (via WHO ICTRP)